Patients with heart failure (HF) and a preserved (>40%) left ventricular ejection fraction (LVEF) have few therapeutic options. Sodium glucose cotransporter 2 inhibitors have been shown to reduce the risk of hospitalization for HF in patients with HF and a reduced LVEF. It is unknown if these drugs can provide a similar benefit for patients with HF with a preserved LVEF … [Read more...] about EMPEROR Preserved: Empagliflozin in heart failure with preserved ejection fraction
General cardiology
Top Interventional Cardiology Conferences & Courses 2022
Worldwide interventional cardiology conferences and courses offer important learning and networking opportunities in an ever evolving field. Hereby is our curated list (in order, by date) of the top interventional cardiology conferences and courses planned for 2022. Also review the main general cardiology conferences that are listed in our Top Cardiology Conferences 2022. … [Read more...] about Top Interventional Cardiology Conferences & Courses 2022
Value of real-world DOAC data on atrial fibrillation treatment
Following the approval of direct oral anticoagulants (DOACs) a number of real-world studies were initiated to look at their impact on atrial fibrillation (AF) patients seen in daily practice. Unlike randomized controlled trials, real-world studies do not have strict exclusion criteria and look include many AF patients with various comorbidities. However, there are fundamental … [Read more...] about Value of real-world DOAC data on atrial fibrillation treatment
Top Cardiology Conferences 2022
Looking ahead here is our curated list (in order, by date) of the top cardiology conferences planned for 2022. 19th International Conference on Pediatrics and Pediatric Cardiology May 18-19, 2022 Location: Amsterdam, Netherlands & Online The main focus and theme for the Pediatric Cardiology 2022 conference is “Emerging interventions in Pediatric … [Read more...] about Top Cardiology Conferences 2022
Rivaroxaban plus aspirin confers mortality benefit over aspirin alone
The COMPASS trial (NCT01776424) compared outcomes of subjects with chronic coronary artery disease (CAD) or peripheral artery disease (PAD) taking rivaroxaban plus aspirin with subjects taking aspirin alone. The primary outcome (a composite of myocardial infarction, stroke, or cardiovascular [CV] death) was decreased by 24% in the group taking rivaroxaban plus aspirin. … [Read more...] about Rivaroxaban plus aspirin confers mortality benefit over aspirin alone